Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amphastar Pharmaceuticals (AMPH) Other Non-Current Liabilities: 2014-2025

Historic Other Non-Current Liabilities for Amphastar Pharmaceuticals (AMPH) over the last 11 years, with Sep 2025 value amounting to $29.3 million.

  • Amphastar Pharmaceuticals' Other Non-Current Liabilities rose 8.26% to $29.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $29.3 million, marking a year-over-year increase of 8.26%. This contributed to the annual value of $20.9 million for FY2024, which is 7.80% down from last year.
  • Latest data reveals that Amphastar Pharmaceuticals reported Other Non-Current Liabilities of $29.3 million as of Q3 2025, which was up 5.30% from $27.8 million recorded in Q2 2025.
  • Amphastar Pharmaceuticals' Other Non-Current Liabilities' 5-year high stood at $29.3 million during Q3 2025, with a 5-year trough of $13.4 million in Q1 2021.
  • Over the past 3 years, Amphastar Pharmaceuticals' median Other Non-Current Liabilities value was $20.9 million (recorded in 2024), while the average stood at $21.6 million.
  • Examining YoY changes over the last 5 years, Amphastar Pharmaceuticals' Other Non-Current Liabilities showed a top increase of 72.22% in 2024 and a maximum decrease of 7.80% in 2024.
  • Quarterly analysis of 5 years shows Amphastar Pharmaceuticals' Other Non-Current Liabilities stood at $15.7 million in 2021, then fell by 6.95% to $14.6 million in 2022, then spiked by 55.98% to $22.7 million in 2023, then decreased by 7.80% to $20.9 million in 2024, then climbed by 8.26% to $29.3 million in 2025.
  • Its Other Non-Current Liabilities was $29.3 million in Q3 2025, compared to $27.8 million in Q2 2025 and $24.4 million in Q1 2025.